OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder

INTRODUCTION: A prespecified pooled analysis of two placebo-controlled, phase 3 trials evaluated whether the number of prior anticholinergics used or reason for their discontinuation affected the treatment response to onabotulinumtoxinA 100U in overactive bladder (OAB) patients with urinary incontin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Clin Pract
Main Authors: Sievert, K-D, Chapple, C, Herschorn, S, Joshi, M, Zhou, J, Nardo, C, Nitti, V W
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2014
Assuntos:
Urology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282287/
https://ncbi.nlm.nih.gov/pubmed/24754838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12443
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados